Deals this week: Ixaltis, Arbutus Biopharma, Gesynta Pharma

6th October 2017 (Last Updated October 6th, 2017 09:42)

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.

French specialist pharmaceutical company Ixaltis has signed an agreement with Swiss biopharmaceutical company Xigen for worldwide rights to a compound being developed by the latter, targeting urogenital diseases.

The transaction enables the two companies to strengthen their urinary disorders product portfolio.

Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares.

Subscribed to by Roivant Sciences, the placement will enable Arbutus to accelerate the development of its HBV drug pipeline.

Research company Gesynta Pharma has acquired pharmaceuticals developer Orexo’s assets relating to the OX-MPI programme.

"Canadian biopharmaceutical company Arbutus Biopharma plans to raise $116.4m through the private placement of convertible preferred shares."

The deal will help the company to advance its OX-MPI project into the clinical stage.

Both companies involved in the deal are based in Sweden.

KSQ Therapeutics has secured $76m in a venture financing round led by Flagship Pioneering.

The US-based biotechnology company plans to use the funds in order to advance its research and development activities.

Bermuda-based biopharmaceutical company SELLAS Life Sciences Group (SELLAS) has signed a clinical trial collaboration agreement with US-based pharmaceutical company Merck & Co’s subsidiary.

The two companies will carry out a combination clinical trial with galinpepimut-S and KEYTRUDA, under the agreement.

The trial will target multiple cancer types, including haematologic malignancies and solid tumours.